RT Journal Article
T1 Recent Advances in Multimodal Molecular Imaging of Cancer Mediated by Hybrid Magnetic Nanoparticles
A1 Luengo Morato, Yurena
A1 Ovejero Paredes, Karina
A1 Marciello, Marzia
A1 Filice, Marco
A1 Lozano Chamizo, Laura
AB Cancer is the second leading cause of death in the world, which is why it is so important to make an early and very precise diagnosis to obtain a good prognosis. Thanks to the combination of several imaging modalities in the form of the multimodal molecular imaging (MI) strategy, a great advance has been made in early diagnosis, in more targeted and personalized therapy, and in the prediction of the results that will be obtained once the anticancer treatment is applied. In this context, magnetic nanoparticles have been positioned as strong candidates for diagnostic agents as they provide very good imaging performance. Furthermore, thanks to their high versatility, when combined with other molecular agents (for example, fluorescent molecules or radioisotopes), they highlight the advantages of several imaging techniques at the same time. These hybrid nanosystems can be also used as multifunctional and/or theranostic systems as they can provide images of the tumor area while they administer drugs and act as therapeutic agents. Therefore, in this review, we selected and identified more than 160 recent articles and reviews and offer a broad overview of the most important concepts that support the synthesis and application of multifunctional magnetic nanoparticles as molecular agents in advanced cancer detection based on the multimodal molecular imaging approach.
PB MDPI
YR 2021
FD 2021
LK https://hdl.handle.net/20.500.14352/119470
UL https://hdl.handle.net/20.500.14352/119470
LA eng
NO Luengo Morato Y, Ovejero Paredes K, Lozano Chamizo L, Marciello M, Filice M. Recent Advances in Multimodal Molecular Imaging of Cancer Mediated by Hybrid Magnetic Nanoparticles. Polymers 2021;13:2989. https://doi.org/10.3390/polym13172989
NO Instituto de Salud Carlos III (España)
NO Comunidad de Madrid
NO European Commission
DS Docta Complutense
RD 19 dic 2025